Selecxine, a start-up pharmaceutical development company, 

attracted USD 12 million worth of series A.

As a start-up company, focused on the development of monoclonal antibody through its own platform technology, Selecxine plans to accelerate the development of immune-mediated anti-cancer drugs using cytokine and antibody conjugates through this attractive investment.

On May 7, Selecxine announced that they completed series A that raised ₩13.7 billion by issuing redeemable convertible preference shares for domestic venture capital, securities firm, and strategic investment companies.

SJ Investment Partners, Stonebridge Ventures, POSCO Technology Investment/Krunventures, POSCO Technology Investment/BMVentures, Medytox Venture Investment, Quantum Ventures Korea, Hanhwa Investment & Securities, and Lighthouse Combined Investment participated in this series A investment.

Selecxine was found in December 2018 by its current CEO, Dr. Jun-Young Lee, a PhD in immunology from Pohang University of Science and Technology. It aims to develop antibodies that bind to specific epitopes of multi-functional biomaterials, such as cytokines or cytokine receptors. It also focuses on the development of immune-mediated therapeutics, such as anti-cancer immunotherapeutics, through the platform technology that modulates or amplifies the desired signal.

Recently, it has accelerated the development of new drugs by concluding an outsourced production contract with the global CDMO GenScript.

The first drug in the pipeline, SLC-3010, is a cytokine-antibody conjugate-based immune-mediated anti-cancer drug. Through in vitro and in vivo experiments, Selecxine confirmed that SLC-3010 selectively activated the anti-cancer immune response and suppressed various types of cancer.

“The attractive investment at this time has provided a foundation for the stable development of SLC-3010, which is currently in the pipeline. The pre-clinical trials of SLC-3010, that will be initiated in the second half of this year, and the subsequent clinical trials will also gain momentum” said the CEO, Jun-Young Lee.

Selecxine is headquartered in the Pohang University of Science and Technology Biotech center and has established its Seoul office, in collaboration with a laboratory in Songpa-gu, Seoul last year to conduct research and development work.